OTLK: Outlook Therapeutics, Inc. Stock

by  •  • Comments Off on OTLK: Outlook Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 207.82
Enterprise Value ($M) 234.01
Book Value ($M) -24.34
Book Value / Share -1.04
Price / Book -8.54
NCAV ($M) -25.64
NCAV / Share -1.10
Price / NCAV -8.11

Profitability (mra)
Return on Invested Capital (ROIC) -4.22
Return on Assets (ROA) -0.95
Return on Equity (ROE) -4.91

Liquidity (mrq)
Quick Ratio 0.44
Current Ratio 0.44

Balance Sheet (mrq) ($M)
Current Assets 20.39
Assets 21.68
Liabilities 46.03
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income -53.13
Net Income -58.98
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -42.97
Cash from Investing 0.00
Cash from Financing 48.97

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-17 13D/A Syntone Ventures LLC 11.40 -85.99
04-08 13G Great Point Partners Llc 9.99
03-28 13G Tang Capital Partners Lp 9.99
03-28 13G Velan Capital Investment Management LP 5.60
03-20 13D/A GMS Ventures & Investments 37.00 -87.00
01-31 13D/A BioLexis Pte Ltd. 6.40 -14.03

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-02-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-01-24 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K/A (Amendment No. 1) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED SEPTEMBER 30, 2023 ☐TRANSITION REPOR
2023-12-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K
2023-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2023-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-05-01 30,917 188,262 16.42
2024-04-30 54,209 192,140 28.21
2024-04-29 29,096 140,793 20.67
2024-04-26 23,904 37,920 63.04

(click for more detail)

Similar Companies
ORGO – Organogenesis Holdings Inc. ORGS – Orgenesis Inc.
ORMP – Oramed Pharmaceuticals Inc. PALI – Palisade Bio, Inc.
PCSA – Processa Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io